Proceedings · Session S-911 · filed November 19, 2026
Translational ScienceSession paper
CBD Beats Placebo on Motor Skills in Boys With Severe Autism
A UC San Diego trial of 30 boys aged 7–14 with severe autism found CBD significantly beat placebo on motor scores; communication gains appeared within the CBD group but not against placebo.
By Priya Raman2 min read500 words
Summary
- Study of 30 boys aged 7–14 with severe autism, ~73% nonverbal, published in Journal of Autism and Developmental Disorders
- CBD (Epidiolex, up to 20 mg/kg daily) beat placebo significantly on motor scores in 8-week crossover periods
- Motor difference driven mainly by worsening under placebo, not improvement from baseline under CBD
- Significant within-group gains in receptive and written communication; no significant CBD-vs-placebo difference on communication
- Builds on May 2025 primary trial showing two-thirds improved behaviorally but a substantial placebo effect

A randomized, double-blind trial found that purified CBD significantly outperformed placebo on motor skill measures in boys with severe autism, according to a study published November 2026 in the Journal of Autism and Developmental Disorders by researchers at the University of California San Diego.
The analysis followed 30 boys, aged 7 to 14, all with autism and substantial cognitive and behavioral challenges. Approximately 73% of participants were classified as nonverbal. Each boy received both treatments in sequence: eight weeks of CBD, a four-week washout, then eight weeks of placebo, in randomized order.
What did the trial measure?
Researchers administered pharmaceutical-grade cannabidiol as Epidiolex, the FDA-approved purified CBD formulation, at doses reaching 20 milligrams per kilogram of body weight daily. They assessed adaptive functioning with the Vineland Adaptive Behavior Scales, Third Edition, a standardized instrument covering communication, daily living skills, socialization and motor abilities.
The new publication examined secondary outcomes not detailed in the original trial report from May 2025, which found that roughly two-thirds of participating boys showed behavioral improvements on blinded clinical assessments during CBD treatment — but also documented a substantial placebo effect, with no significant difference between treatments on primary behavioral measures.
Where did CBD show an effect?
Motor skills produced the clearest separation. Standardized and raw motor scores both showed statistically significant differences favoring CBD over placebo.
The mechanism of that difference deserves scrutiny, however. Researchers reported it was driven primarily by worsening motor scores during placebo periods, not by statistically significant improvement from baseline under CBD. For portfolio and clinical decisions, that distinction matters: the treatment arms diverged, but the data do not cleanly show CBD raising motor performance above starting levels.
Communication told a different story. Within the CBD group, boys showed statistically significant improvements against their own pretreatment scores in receptive communication — understanding spoken language — and in written communication. Expressive communication and personal daily living skills neared statistical significance.
Crucially, these communication gains did not reach statistical significance when CBD was compared directly with placebo on overall communication measures. They are within-group changes, not head-to-head victories, and the study authors framed them accordingly.
Why raw scores mattered
The participants' substantial developmental challenges made some improvements hard to detect using conventional standardized scores. By examining raw scores alongside standardized ones, the researchers identified changes that standard norms would have missed — a methodological note relevant to any team designing trials in profoundly affected populations, where floor effects on validated instruments can mask real functional change.
The trial did not demonstrate broad improvement across every adaptive functioning domain. Its contribution is narrower: additional evidence that purified CBD may benefit specific functional areas in some children with severe autism, with the motor finding the most robust and the communication signal suggestive but unconfirmed against placebo.
What comes next?
The UC San Diego team called for larger clinical trials enrolling participants across different levels of autism severity to determine whether the observed communication improvements translate into consistent benefits compared with placebo.
via themarijuanaherald.com (Source)
Filed under
- cannabidiol-cbd
- autism
- randomized-clinical-trial
- motor-skills
- adaptive-functioning
More from Priya Raman
Show full bio
Staff writer covering money, funding and market shifts around research and development at Hypothesis Wire.
289 articles
References
- Jazz Pharmaceuticals Wins Two U.S. Patents Covering CBD-C4 and CBD Derivatives
- FDA Proposes First Drug-to-Supplement Path That Could Reach CBD
- Two-Year UK Study Tracks 38% PTSD Symptom Drop in Cannabis Patients
- Takeda Launches First Orexin Agonist for Narcolepsy Type 1 in US
- FDA Clears First Factor XIa Inhibitor, Setting Benchmark for a Crowded Class